Alglucosidase
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 259 publications
Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data.
Journal: Journal of comparative effectiveness research
Published: February 27, 2026
Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis.
Journal: Health technology assessment (Winchester, England)
Published: February 16, 2026
Early enzyme replacement therapy in late-onset Pompe disease diagnosed by newborn screening.
Journal: Molecular genetics and metabolism
Published: January 25, 2026
Response to: Correspondence on 'Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements' by Barzel et al.
Journal: European journal of hospital pharmacy : science and practice
Published: December 31, 2025
Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel et al.
Journal: European journal of hospital pharmacy : science and practice
Published: December 23, 2025
Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions.
Journal: Frontiers in neurology
Published: November 29, 2025
First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease.
Journal: Journal of neurology
Published: November 19, 2025
Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study.
Journal: Molecular genetics and metabolism
Published: November 11, 2025
Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: November 09, 2025
A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience.
Journal: Current opinion in immunology
Published: October 18, 2025
Successful desensitization to alglucosidase alfa in a very young infant with Pompe disease.
Journal: Journal of pediatric endocrinology & metabolism : JPEM
Published: October 18, 2025
Last Updated: 04/28/2026